ESMO 2025 | Predictive model for resistance to neoadjuvant PD-1 in melanoma
Ines Pires da Silva, MD, PhD, Melanoma Institute Australia, Sydney, Australia, discusses a study developing a clinical and multi-omics model to predict resistance to neoadjuvant PD-1 in stage III–IV melanoma. Using clinical data, tumor mutational burden, BRAF status, and gene expression profiling, the model identified patients unlikely to achieve major pathological response. Combining clinical and omics features improved predictive accuracy, supporting patient selection for trials exploring novel neoadjuvant strategies. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So basically, we took the data that we have from our NEO platform, which is a neoadjuvant translational research platform. So we took the data from these patients and we looked at the NTPD1-treated patients. And our goal was to identify those patients resistant to NTPD1 monotherapy. So we can then identify this group of resistant patients that they can be involved in novel combination immunotherapies...
So basically, we took the data that we have from our NEO platform, which is a neoadjuvant translational research platform. So we took the data from these patients and we looked at the NTPD1-treated patients. And our goal was to identify those patients resistant to NTPD1 monotherapy. So we can then identify this group of resistant patients that they can be involved in novel combination immunotherapies. So what we did, we took the approach of taking clinical data, RNA, and also DNA sequencing data. And then, of course, with a very heavy statistical analysis, we took into account so many different factors and we came up with six independent models taking into one feature or more than one feature and at the end we have the consensus model and with that we have AUC of 0.84 which is not a hundred percent but it’s very high so that will enrich our future cohorts in these resistant patients
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
